Aerpio Pharmaceuticals Inc

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

CINCINNATI, March 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 in indications in which the Company believes that activation of Tie2 may have therapeutic potential, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.

Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Quantum Leap Healthcare Collaborative-sponsored I-SPY COVID Trial will not further test Aerpio Pharmaceuticals Inc's (NASDAQ: ARPO) razuprotafib. Razuprotafib was chosen because it was believed to stabilize and repair the lung's blood vessels and improve gas exchange.

Aerpio Pharmaceuticals' Razuprotafib Dropped From Collaborative COVID-19 Trial

SAN FRANCISCO and CINCINNATI, March 05, 2021 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio Pharmaceuticals (Nasdaq: ARPO) drug, razuprotafib. Razuprotafib was chosen for testing in the I-SPY COVID Trial because it is hypothesized to stabilize and repair the blood vessels in the lung and improve gas exchange.

Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial

Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?

Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.

Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs

Aerpio Pharmaceuticals (ARPO) has been struggling lately, but the selling pressure may be coming to an end soon.

Aerpio Pharmaceuticals (ARPO) Sees Hammer Chart Pattern: Time to Buy?

CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources, which amounted to $47.3 million as of September 30, 2020.

Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial

Does Aerpio Pharmaceuticals, Inc. (ARPO) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Aerpio Pharmaceuticals, Inc. (ARPO) a Strong Momentum Stock: Buy Now?

AnPac Bio-Medical Science Co

Arvinas Inc

Synlogic

Veru

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific updates. Arvinas Inc (NASDAQ: ARVN): The smid-cap biopharma announced clinical program updates for its protein degraders ARV-471 and ARV-110.

5 Biopharma Stocks Making Big Moves Monday

Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group.

Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial

Repligen

TRACON Pharmaceuticals

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

3 Biotech Stocks to Buy on First Vaccine Approval Optimism

Aerpio Pharmaceuticals, Inc. (ARPO) Management on Q3 2020 Results - Earnings Call Transcript

Conference Call Today, November 10 , 2020 at 8:30 a.m. EST

Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update

CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome (“ARDS”) associated with COVID-19 infections, will release its financial results for the third quarter ended September 30, 2020, before the market open on Tuesday, November 10, 2020, and host a webcast and conference call at 8:30am ET.

Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10

Call Taking Place on Thursday, November 12th @ 11amET Call Taking Place on Thursday, November 12th @ 11amET

Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19

The trial in moderate-to-severe patients is Aerpio's second clinical trial in COVID-19 patients and is funded in part by the U . S . military

Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19

Topline Data Expected 4Q 2020 Topline Data Expected 4Q 2020

Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial

SAN FRANCISCO and CINCINNATI, Sept.  01, 2020  (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT04488081), a phase 2 platform trial aimed at improving treatment of acute respiratory distress syndrome (ARDS) in severely ill COVID-19 (adult) patients. Further details about the study can be found  here .

Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients

Aerpio Pharmaceuticals' (ARPO) Management on Q2 2020 Results - Earnings Call Transcript

Conference Call Today, August 12, 2020 at 8:30 a.m. EDT

Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update

CINCINNATI, Aug.  10, 2020  (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, will release its financial results for the second quarter ended June 30, 2020, before the market open on Wednesday, August 12, 2020, and host a webcast and conference call at 8:30am ET.

Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12

CINCINNATI, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC) announced today that an agreement has been reached to evaluate razuprotafib in a new randomized, investigational trial for the prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) in adult patients with moderate to severe COVID-19 as part of MTEC-20-09-COVID-19 Treatment Military Infectious Disease Research Program (MIDRP) “Development of Treatments for COVID-19.”  MTEC will provide up to $5.1 million in funding toward the clinical trial.  Aerpio will support the trial with “in kind” spending in the amount of $2.8 million. MTEC is a 501(c)3 non-profit organization constructed by the U.S. Army Medical Research and Development Command (USAMRDC). The Medical Technology Enterprise Consortium (MTEC) was established as an enterprise partnership including industry and academia to facilitate research and development activities. Protecting U.S. forces from COVID-19 is a key priority for the U.S. military. The partnership between Aerpio and MTEC will provide resources to support a second COVID-19 Phase 2 clinical trial with razuprotafib, a drug candidate being investigated for its potential to prevent and treat the severe respiratory distress observed in COVID-19 patients.

Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19

In the latest trading session, Aerpio Pharmaceuticals, Inc. (ARPO) closed at $1.26, marking a +1.61% move from the previous day.

Aerpio Pharmaceuticals, Inc. (ARPO) Outpaces Stock Market Gains: What You Should Know

Is  (ARPO) Outperforming Other Medical Stocks This Year?

Is Aerpio Pharmaceuticals (ARPO) Outperforming Other Medical Stocks This Year?

As of late, it has definitely been a great time to be an investor in Aerpio Pharmaceuticals.

News for Aerpio Pharmaceuticals Inc Stock (ARPO)